Cheng Pin-Nan, Chang Ting-Tsung
National Cheng Kung University, Medical College and Hospital, Tainan, Taiwan, ROC.
Expert Rev Anti Infect Ther. 2008 Oct;6(5):569-79. doi: 10.1586/14787210.6.5.569.
Entecavir has demonstrated safety and efficacy in the treatment of chronic hepatitis B infection. It is the prototype for the cyclopentane class of nucleoside/nucleotide chronic hepatitis B antiviral agents. It has a high potency and, due to its structural formula and mechanism of action, entecavir is associated with emergence of minimal resistance in the long-term treatment of nucleoside-naive patients. Research suggests that long-term treatment may be required for chronic hepatitis B patients, especially those who acquire HBV early in life, to achieve maximum viral suppression and improve outcomes. Several recent studies have evaluated the long-term safety, efficacy and development of resistance in nucleoside-naive patients treated with entecavir. Results indicate that the long-term use of entecavir is well tolerated and associated with continuous clinical improvement -- with an increasing number of patients achieving undetectable levels of HBV DNA, HBeAg seroconversion and minimal resistance. These data underscore the position of entecavir for first-line therapy and highlight its role in the long-term treatment of chronic hepatits B.
恩替卡韦在治疗慢性乙型肝炎感染方面已显示出安全性和有效性。它是环戊烷类核苷/核苷酸慢性乙型肝炎抗病毒药物的原型。它具有高效力，并且由于其结构式和作用机制，恩替卡韦在初治核苷类药物患者的长期治疗中与极低的耐药发生率相关。研究表明，慢性乙型肝炎患者可能需要长期治疗，尤其是那些在生命早期感染乙肝病毒的患者，以实现最大程度的病毒抑制并改善预后。最近的几项研究评估了初治核苷类药物患者使用恩替卡韦的长期安全性、有效性和耐药性发展情况。结果表明，恩替卡韦的长期使用耐受性良好，并与持续的临床改善相关——越来越多的患者实现了乙肝病毒DNA检测不到、HBeAg血清学转换以及极低的耐药发生率。这些数据强调了恩替卡韦作为一线治疗药物的地位，并突出了其在慢性乙型肝炎长期治疗中的作用。
